Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | AQST | Common Stock | Gift | $0 | -40K | -16.68% | $0.00 | 200K | Dec 2, 2024 | See Footnote | F1 |
holding | AQST | Common Stock | 12.6K | Dec 2, 2024 | Direct | ||||||
holding | AQST | Common Stock | 1.69M | Dec 2, 2024 | See Footnotes | F2, F3, F4 | |||||
holding | AQST | Common Stock | 3.47M | Dec 2, 2024 | See Footnotes | F2, F3, F5 | |||||
holding | AQST | Common Stock | 2.66M | Dec 2, 2024 | See Footnotes | F2, F3, F6 | |||||
holding | AQST | Common Stock | 47.1K | Dec 2, 2024 | See Footnotes | F2, F3, F7 | |||||
holding | AQST | Common Stock | 1.95M | Dec 2, 2024 | See Footnotes | F2, F3, F8 | |||||
holding | AQST | Common Stock | 2.73K | Dec 2, 2024 | See Footnote | F9 |
Id | Content |
---|---|
F1 | These shares of common stock of Aquestive Therapeutics, Inc. (the "Issuer") are held by family trusts and entities controlled by Douglas K. Bratton. Such shares of common stock were acquired in previously reported in-kind pro rata distributions for no consideration without a change in pecuniary interest. |
F2 | These shares of common stock of the Issuer are beneficially owned, as indicated, by MonoLine Partners, L.P. ("MonoLine"), MonoLine Rx, L.P. ("Monoline Rx"), MonoLine Rx II, L.P. ("Monoline II"), and MonoLine Rx III, L.P. ("Monoline III"), respectively. Monoline, Monoline Rx, Monoline II, and Monoline III are referred to herein collectively as the "Monoline Entities" and each individually a "Monoline Entity". Bratton Capital Management, L.P. ("Bratton Capital Management") is the general partner of each of the Monoline Entities. Bratton Capital, Inc. ("Bratton") is the general partner of Bratton Capital Management. Douglas K. Bratton is the sole director and President of Bratton and has voting and investment power over all shares held by the Monoline Entities. |
F3 | Bratton Capital Management, Bratton, and Mr. Bratton may each be deemed to own beneficially all shares beneficially owned by the Monoline Entities, and Bratton and Mr. Bratton may be deemed to beneficially own all shares held by Monosol (as defined below). Each such entity and Mr. Bratton disclaims beneficial ownership of the reported securities except to the extent of its or his respective pecuniary interest therein. |
F4 | These shares of common stock of the Issuer are beneficially owned by Monoline Rx. |
F5 | These shares of common stock of the Issuer are beneficially owned by Monoline II. |
F6 | These shares of common stock of the Issuer are beneficially owned by Monoline III. |
F7 | These shares of common stock of the Issuer are beneficially owned by MonoSol Rx Genpar, L.P. ("Monosol"). Bratton is the general partner of Monosol. Douglas K. Bratton is the sole director and President of Bratton and has voting and investment power over all shares held by Monosol. |
F8 | These shares of common stock of the Issuer are beneficially owned by Monoline. |
F9 | These shares of common stock of the Issuer are held by Douglas K. Bratton's spouse. Such shares of common stock were acquired by Douglas K. Bratton's spouse in previously reported in-kind pro rata distributions for no consideration without a change in pecuniary interest. |